SCHEMBL4181786

SCHEMBL4181786

O=C(Nc1ccnc(N2CCN(C3CCCC3)CC2)c1)Oc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
MAPT P10636 4/20 0.45
GAA P10253 3/20 0.45
KDM4E B2RXH2 2/20 0.45
USP2 O75604 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
HRH3 Q9Y5N1 3/20 0.44
GRIN2D O15399 2/20 0.44
GRIN3B O60391 2/20 0.44
GRIN1 Q05586 2/20 0.44
GRIN2A Q12879 2/20 0.44
GRIN2B Q13224 2/20 0.44
GRIN2C Q14957 2/20 0.44
GRIN3A Q8TCU5 2/20 0.44
PTPN11 Q06124 1/20 0.43
CPT2 P23786 1/20 0.41
CPT1A P50416 1/20 0.41
CPT1B Q92523 1/20 0.41
HTR1A P08908 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4950777 0.85 HRH3 (0.45) ALDH1A1MAPTKDM4EKMT2AHRH3
SCHEMBL4947619 0.85 GRIN2D (0.51) ALDH1A1HRH3GRIN2DGRIN3BGRIN1
SCHEMBL4949632 0.84 HRH3 (0.44) ALDH1A1MAPTKDM4EKMT2AHRH3
SCHEMBL4950151 0.84 HRH3 (0.44) ALDH1A1MAPTKDM4EKMT2AHRH3
SCHEMBL2825785 0.84 KDM4E (0.48) ALDH1A1MAPTGAAKDM4EUSP2
Cyclopentane SCHEMBL4947613 0.83 HRH3 (0.46) ALDH1A1MAPTGAAKDM4EKMT2A
SCHEMBL4949994 0.83 HRH3 (0.46) ALDH1A1MAPTGAAKDM4EKMT2A
Cyclopropane SCHEMBL4950789 0.83 HRH3 (0.46) ALDH1A1MAPTGAAKDM4EKMT2A
Cyclohexane SCHEMBL4949278 0.83 HRH3 (0.46) ALDH1A1MAPTGAAKDM4EKMT2A
SCHEMBL4949845 0.82 HRH3 (0.43) ALDH1A1MAPTKDM4EHRH3GRIN2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612076-B2 Piperazinyl-pyridine derivatives HOFFMAN-LA ROCHE INC. (US) 2009-11-03 US disclosed
US-20090042903-A1 PIPERAZINYL-PYRIDINE DERIVATIVES NETTEKOVEN MATTHIAS HEINRICH 2009-02-12 US disclosed
US-7456175-B2 Piperazinyl-pyridine derivatives HOFFMAN-LA ROCHE INC. (US) 2008-11-25 US disclosed
EP-1828134-B1 PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS HOFFMANN LA ROCHE (CH) 2008-10-29 EP disclosed
US-20060135528-A1 Piperazinyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135528-A1 Piperazinyl-pyridine derivatives HRH4, HRH3, H1-3 ALDH1A1 814/4885MAPT 2843/4885GAA 1999/4885
US-20090042903-A1 PIPERAZINYL-PYRIDINE DERIVATIVES HRH4, HRH3, H1-3 ALDH1A1 814/4885MAPT 2843/4885GAA 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.